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Adventitious agent contamination of cell culture-based biomanufacturing operations for the production of protein 
and monoclonal antibody biotherapeutics are infrequent, but when they do occur, they are very costly, impact 
manufacturing operations, and can potentially impact patient safety and product supply. In response to this need, 
the MIT Consortium on Adventitious Agent Contamination in Biomanufacturing (CAACB) began the confidential 
collection and analysis of industry-wide viral contamination data with an emphasis on “lessons learned”. This 
presentation will cover the learnings from this study, including identified industry risks and best practices to 
mitigate those risks. Some of the key findings which have significant implications to the emerging cell therapy 
industry are: 
 
1) Raw materials, including non-animal-based raw materials, may be a potential source of viral 
contamination and stringent raw material testing and vendor selection and auditing programs are critical. 
2) Traditional viral tests, including in vitro testing and PCR, have contributed to false-positive events, which 
may take extended times to resolve prior to release of raw materials, process intermediates, or final product. 
3) The time frames needed for viral testing in general, and for investigation of positive viral tests, can range 
from weeks to months, and are not compatible with the requirements for near real-time release testing for some 
cell therapy products.    
4) Viral testing programs, and potential investigations of positive results, are quite expensive, and 
application to the autologous cell therapy space will be challenging. 
 
 
 
